Satellite Banner
Molecular & Clinical Diagnostics
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Personalized Medicine Drives Uptake of Next-generation Sequencing in Europe

Published: Saturday, May 31, 2014
Last Updated: Saturday, May 31, 2014
Bookmark and Share
Future of DNA sequencing will shift from a laboratory-based setup to point of care testing in the next 5 years.

The Western European next-generation sequencing (NGS) market is poised for steady growth, owing to the emergence of new applications such as non-invasive prenatal testing and comprehensive oncology panels.

NGS manufacturers are further tapping into this space by forming partnerships with molecular diagnostic companies to quicken NGS adoption in clinics, particularly for oncology-based testing.

New analysis from Frost & Sullivan, Western European Next-generation Sequencing Markets, finds that the market earned revenues of $381.9 million in 2013 and estimates this to reach $697.3 million in 2018.

Major growth areas will include pre-implantation genetic diagnosis, oncology testing, infectious disease, human leukocyte antigen typing, and companion diagnostics. The total market, as defined by this study, includes next-generation sequencers and reagents for both research and diagnostic use.

“Companies within the space of personalized healthcare are designing instruments to target specific needs across the clinical diagnostic spectrum, therefore adding NGS capabilities to their portfolio,” said Frost & Sullivan Healthcare Senior Industry Analyst Divyaa Ravishankar. “As long as the genomic era interfaces with personalized medicine, NGS uptake will continue.”

A key restraint curbing market potential is the lack of reimbursement norms, which leads to geographical disparity in terms of NGS test availability. The consequent need for the cross-border shipping of samples, prominent in Belgium, France, Italy, Spain, the UK, and Germany, makes gauging the reimbursement scenario extremely tough for market participants.

Hence, NGS vendors must establish early, robust partnerships with regulatory bodies and devise effective business models to gain rapid regulatory clearance. Manufactures must also look to adhere to the CE marking rather than laboratory developed test (LDT) policies to enable the easy generation of reimbursement codes.

“Given the recent technology advancements in Europe, the future of DNA sequencing will move away from a laboratory-based setup to point of care testing,” predicted Ravishankar. “Frost & Sullivan expects NGS to become an area of interest to all market leaders within the point of care testing domain, as they strive to bring sequencing from ‘bench to bedside’.”

As the applications of NGS and molecular diagnostics expand to include crop improvement as well as food and safety testing, ready-to-use sequencing-based tests that generate data from raw samples will emerge as important tools in the Western European market.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Monday, August 24, 2015
Changing Phase of Biomarkers
Discover the current scenario and changing business models of the biomarkers field.
Monday, April 13, 2015
Companion Diagnostics Benefit from Fewer Regulatory Barriers in Europe
Future revisions to in-vitro diagnostics laws will offset the launch of new tests, in a market expected to soar to $1,295.1 million in 2018.
Thursday, June 26, 2014
Emerging Technologies Redefine Infectious Disease Diagnostics
The largest opportunities lie in the developing regions of Asia, Africa and Latin America.
Wednesday, April 23, 2014
Live Cell Imaging Revolutionizes Disease Diagnostics and Drug Discovery
Stakeholder collaboration will be crucial to convert these developments into clinically meaningful tests.
Friday, March 21, 2014
Automated Anatomic Pathology Labs Transform Global Tissue Diagnostics Market
Offering attractive procurement strategies will boost adoption of high-end tools.
Thursday, February 06, 2014
Increasing Public Health Awareness Intensifies Global Uptake of Autoimmune Disease Diagnostics
Frost & Sullivan: Hospitals and laboratories look for cost-effective test panels enabling simultaneous autoimmune diseases testing.
Monday, October 14, 2013
Demand for Rapid Results, Non-invasive Methods and Automated Monitoring Driving the Global POCT Market
Frost & Sullivan finds healthcare infrastructure modernization in developing nations and expanding application scope boosts opportunities for POCT.
Monday, September 30, 2013
Increasing Prevalence of Heart Disease Drives Growth of Cardiac Biomarkers Diagnostics Market
Participants need to focus on product customization, ease-of-use and reliability.
Monday, April 22, 2013
High Degree of Disease Prevalence Sustains Diabetes Diagnostics Market in Europe
Companies can increase profits by offering customized testing solutions with accurate, result-oriented features.
Thursday, November 29, 2012
Analysis for Tomorrow's Clinical Approach to Diagnostics, Therapy, Intervention and Monitoring Solutions
As the diverse areas of healthcare forge ahead into overlapping mechanisms and treatments, so too must medical technologies reform to solve several challenges via streamlined remedies.
Thursday, March 22, 2012
Converging towards Integrated Healthcare: A Frost & Sullivan Think Tank on Megatrends Affecting the Healthcare Industry
A clear separation between Medical Devices, Healthcare Technologies and Life Sciences is increasingly difficult. Yet the convergence of all areas opens the door to a new era, enabling personalisation, targeted medicines, new drug delivery mechanisms, and virtual patient monitoring tools, while allowing a preventative approach to healthcare at the same time.
Friday, October 08, 2010
Theranostics Paves the Way for Personalised Medicine in Europe, Says Frost & Sullivan
Strategic Analysis of the European Markets for Theranostics finds that theranostics plays a crucial role in every step of drug development process.
Tuesday, March 23, 2010
Scientific News
Cancer Genetics: Key to Diagnosis, Therapy
When applied judiciously, cancer genetics directs caregivers to the right drug at the right time, while sparing patients of unnecessary or harmful treatments.
Accelerating the Detection of Foodborne Bacterial Outbreaks
The speed of diagnosis of foodborne bacterial outbreaks could be improved by a new technique developed by researchers at the Georgia Institute of Technology.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
New Diagnostic Tool for Familial Mediterranean Fever
A new tool developed by researchers at VIB and Ghent University could improve the process of diagnosing Familial Mediterranean Fever.
'Lab on the Skin' for Sweat Analysis
Northwestern University researchers develop a low-cost wearable electronic device that collects and analyzes sweat for health monitoring.
Molecular Signature for Aggressive Brain Tumor Uncovered
Researchers have identified genetic mutations in a highly agressive brain cancer that distinguishes the agressive, from the benign forms of the cancer.
Malaria Parasite Evades Rapid Test Detection in Children
A study at the University of North Carolina found that gene deletion poses a threat to Malaria eradication efforts.
Novel Urine Test to Predict High-Risk Cervical Cancer
Preliminary studies affirm accuracy and potential cost savings to screen for virus-caused malignancy.
GFC Diagnostics Wins Longitude Prize Discovery Award
The global award was won for the development of a cheap, quick and simple MRSA Test.
Understanding Circulating Tumour Cells
Research team develops new tool to track traveling cancer cells in the bloodstream.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!